![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » XANTHUS PHARMACEUTICALS, INC. EXPANDS ONCOLOGY PIPELINE WITH LATE-STAGE ORAL FLUDARABINE FROM SCHERING AG
XANTHUS PHARMACEUTICALS, INC. EXPANDS ONCOLOGY PIPELINE WITH LATE-STAGE ORAL FLUDARABINE FROM SCHERING AG
Xanthus Pharmaceuticals, Inc., a privately held oncology drug development company, announced that the company has licensed from Schering AG the exclusive right to develop and commercialize oral fludarabine in the United States.
BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31915&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct